Precision treatment selection platform for psychiatry
Extracellular vesicle proteomic prediction models of treatment response
NeuroVesica is unlocking precision psychiatry for improved diagnosis and treatment.
We have built a proprietary transdiagnostic platform to provide prediction of treatment response at the level of the individual.
Our science
EVs are nanoparticles that serve as the body’s dynamic communication system by carrying cargo from one cell or tissue to another. EVs travel in our circulation at very high concentration, making them easily accessible. NeuroVesica uses AI and computational modeling of proteomic EV cargo across clinical trials and cohort studies to identify predictive readouts of treatment response.
Key differentiators
Transdiagnostic biomarkers
NeuroVesica has built a prediction platform to identify treatment responses across psychiatric disorders for better patient allocation and diagnosis.
Dynamic proteomics
NeuroVesica uses EV proteomic modeling to identify response from nonresponse and to differentiate the biology underscoring treatment vs. placebo effect.
Precision measures
Using repeated sampling and longitudinal data sets, NeuroVesica’s platform is built to predict and diagnose at the level of the individual.
Outside the box
NeuroVesica uses its EV proteomic platform to examine the body’s health to predict the brain’s response.
NeuroVesica began as a strong determination to have an impact by translating lab research into precision psychiatry.
Starting at the University of Colorado School of Medicine, Anschutz campus, with a research partnership between expert neuroscientist Tracy L. Bale, Ph.D., and psychiatrist Neill Epperson, M.D., NeuroVesica was born from a recognition that too few research discoveries make it beyond published papers and into the clinical care of individuals with mental illness.
